


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	DARAPLADIB
PRONUNCIATION	dar ap' la dib
THERAPEUTIC CLAIM	Treatment of atherosclerosis

CHEMICAL NAMES

- 1) 1*H*-cyclopentapyrimidine-1-acetamide, *N*-[2-(diethylamino)ethyl]-2-[[4-(4-fluorophenyl)methyl]thio]-4,5,6,7-tetrahydro-4-oxo-*N*-[[4'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]-
- 2) *N*-[2-(diethylamino)ethyl]-2-[2-[(4-fluorobenzyl)sulfanyl]-4-oxo-4,5,6,7-tetrahydro-1*H*-cyclopentapyrimidin-1-yl]-*N*-[[4'-(trifluoromethyl)biphenyl-4-yl]methyl]acetamide

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₃₆ H ₃₈ F ₄ N ₄ O ₂ S
MOLECULAR WEIGHT	666.8
TRADEMARK	Unknown as yet
MANUFACTURER	GlaxoSmithKline
CODE DESIGNATION	SB-480848
CAS REGISTRY NUMBER	356057-34-6